Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation

Urology

Volumn 76, Issue 5, 2010, Pages 1251-1257

  Vassil, Andrew D ^a,b   Murphy, Erin S ^a,b   Reddy, Chandana A ^a,b   Angermeier, Kenneth W ^a,b   Altman, Andrew ^a,b   Chehade, Nabil ^a,b   Ulchaker, James ^a,b   Klein, Eric A ^a,b   Ciezki, Jay P ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Kaiser Permanente ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 78149361039     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.01.010     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. M.R. Cooperberg, D.P. Lubeck, S.S. Mehta, and P.R. Carroll Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol 170 2003 S21 S25 Discussion:S26-S27
3. K.L. Greene, J.E. Cowan, M.R. Cooperberg, M.V. Meng, J. DuChane, and P.R. Carroll Who is the average patient presenting with prostate cancer? Urology 66 2005 76 82
4. K. Wallace, N. Fleshner, M. Jewett, J. Basiuk, and J. Crook Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial J Clin Oncol 24 2006 4158 4162
5. J.W. Colberg, R.H. Decker, A.M. Khan, A. McKeon, L.D. Wilson, and R.E. Peschel Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005 Cancer J 13 2007 229 232
6. A.V. D'Amico, R. Whittington, S.B. Malkowicz, D. Schultz, K. Blank, G.A. Broderick, J.E. Tomaszewski, A.A. Renshaw, I. Kaplan, and C.J. Beard Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer J Am Med Assoc 280 1998 969 974
7. P.A. Kupelian, L. Potters, D. Khuntia, J.P. Ciezki, C.A. Reddy, A.M. Reuther, T.P. Carlson, and E.A. Klein Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
8. L. Potters, E.A. Klein, M.W. Kattan, C.A. Reddy, J.P. Ciezki, A.M. Reuther, and P.A. Kupelian Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation Radiother Oncol 71 2004 29 33
9. S.H. Stokes Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation Int J Radiat Oncol Biol Phys 47 2000 129 136
10. F.A. Vicini, A. Martinez, G. Hanks, A. Hanlon, B. Miles, K. Kernan, D. Beyers, H. Ragde, J. Forman, and J. Fontanesi An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up Cancer 95 2002 2126 2135
11. E.A. Klein, J. Ciezki, P.A. Kupelian, and A. Mahadevan Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 27 2009 67 71
12. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
13. A.J. Vickers, F.J. Bianco, A.M. Serio, J.A. Eastham, D. Schrag, E.A. Klein, A.M. Reuther, M.W. Kattan, J.E. Pontes, and P.T. Scardino The surgical learning curve for prostate cancer control after radical prostatectomy J Natl Cancer Inst 99 2007 1171 1177
14. M. Roach 3rd, G. Hanks, H. Thames Jr., P. Schellhammer, W.U. Shipley, G.H. Sokol, and H. Sandler Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO, Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
15. A.J. Stephenson, M.W. Kattan, J.A. Eastham, Z.A. Dotan, F.J. Bianco Jr., H. Lilja, and P.T. Scardino Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol 24 2006 3973 3978
16. S. Nag, D. Beyer, J. Friedland, P. Grimm, and R. Nath American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer Int J Radiat Oncol Biol Phys 44 1999 789 799
17. J. Romero-Otero, K. Touijer, and B. Guillonneau Laparoscopic radical prostatectomy: contemporary comparison with open surgery Urol Oncol 25 2007 499 504
18. H. Baumert, G. Fromont, R.J. Adorno, D. Cahill, X. Cathelineau, and G. Vallancien Impact of learning curve in laparoscopic radical prostatectomy on margin status: prospective study of first 100 procedures performed by one surgeon J Endourol 18 2004 173 176
19. S.D. Herrell, and J.A. Smith Jr Robotic-assisted laparoscopic prostatectomy: what is the learning curve? Urology 66 2005 105 107
20. J.A. Cadeddu, A.W. Partin, T.L. DeWeese, and P.C. Walsh Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy J Urol 159 1998 173 177 Discussion:177-178
21. C.A. Lawton, M. DeSilvio, M. Roach 3rd, V. Uhl, R. Kirsch, M. Seider, M. Rotman, C. Jones, S. Asbell, and R. Valicenti An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
22. J.P. Ciezki, C.A. Reddy, A.J. Stephenson, K. Angermeier, J. Ulchaker, A. Altman, N. Chehade, and E.A. Klein The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment Urology 75 2010 467 471
23. M.J. Burdick, C.A. Reddy, J. Ulchaker, K. Angermeier, A. Altman, N. Chehade, A. Mahadevan, P.A. Kupelian, E.A. Klein, and J.P. Ciezki Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1439 1445
24. M.S. Cookson, G. Aus, A.L. Burnett, E.D. Canby-Hagino, A.V. D'Amico, R.R. Dmochowski, D.T. Eton, J.D. Forman, S.L. Goldenberg, and J. Hernandez Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes J Urol 177 2007 540 545
25. J.C. Hu, Q. Wang, C.L. Pashos, S.R. Lipsitz, and N.L. Keating Utilization and outcomes of minimally invasive radical prostatectomy J Clin Oncol 26 2008 2278 2284
26. I. Lee, and H. Sandler Hormone therapy and radiotherapy for intermediate risk prostate cancer Semin Radiat Oncol 18 2008 7 14
27. J. Crook, C. Ludgate, S. Malone, G. Perry, L. Eapen, J. Bowen, S. Robertson, and G. Lockwood Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 327 333
28. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial J Am Med Assoc 292 2004 821 827
29. J.P. Ciezki, E.A. Klein, K. Angermeier, J. Ulchaker, N. Chehade, A. Altman, A. Mahadevan, and C.A. Reddy A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy Int J Radiat Oncol Biol Phys 60 2004 1347 1350
30. A.V. D'Amico, D. Schultz, M. Loffredo, R. Dugal, M. Hurwitz, I. Kaplan, C.J. Beard, A.A. Renshaw, and P.W. Kantoff Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer J Am Med Assoc 284 2000 1280 1283